The RAMP system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories.
RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure through company’s commercial partners, Roche and Shionogi and through select international distributors.
Response Biomedical CEO Wayne Kay said that are working to expandtheir market presence throughout Europe, the Middle East and Asia, and are delighted that Cremascoli will represent their RAMP products in Italy.
"Cremascoli’s experience in POCT and their strong infrastructure are an excellent complement to our Company, and we look forward to a successful partnership with them," Kay said.
